EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH
(EEJSAR) ISSN: 2992-4146
©EEJSAR Publications Volume 7 Issue 3 2025

Efficacy of CRISPR/Cas9 Gene Editing in Eradicating HIV Latent Reservoirs in Individuals on Long-term ART

Wambui Kibibi J.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Human Immunodeficiency Virus (HIV) remains a major global health issue, with the persistence of latent viral reservoirs serving as a primary barrier to a functional cure despite the success of antiretroviral therapy (ART). These reservoirs consist of long-lived, HIV-infected cells, primarily in CD4+ T cells, which remain dormant and evade immune detection and ART. CRISPR/Cas9 gene editing offers a promising strategy to target and excise integrated HIV proviral DNA from these reservoirs, potentially leading to viral eradication. This review examined the efficacy of CRISPR/Cas9 in eradicating HIV latent reservoirs in individuals on long-term ART by synthesizing both preclinical and clinical data. The methodology for this article involved an extensive review of current literature, focusing on the molecular mechanisms of CRISPR/Cas9, its applications in HIV research, and the challenges faced in translating these findings into clinical practice. The review discussed promising results from in vitro and animal model studies, highlighting CRISPR/Cas9's ability to exercise proviral DNA and reduce viral loads. Early-phase clinical trials have demonstrated the feasibility and safety of CRISPR/Cas9, though challenges such as off-target effects, delivery efficiency, and residual viral reservoirs remain significant. Future directions include refining gene-editing techniques, exploring combination therapies, and conducting long-term safety studies. Despite challenges, CRISPR/Cas9 holds transformative potential in the pursuit of an HIV cure.

Keywords: CRISPR/Cas9, HIV Latent Reservoirs, Gene Editing, ART (Antiretroviral Therapy), HIV Cure.

INTRODUCTION

Human Immunodeficiency Virus (HIV) remains a global health challenge, with approximately 38 million people living with the virus worldwide [1, 2]. Antiretroviral therapy (ART) has revolutionized HIV management, transforming it from a fatal disease to a chronic condition [3, 4]. However, ART is not a cure. While it effectively suppresses viral replication, it cannot eliminate latent viral reservoirs dormant HIV-infected cells that persist in the body and can reactivate upon treatment interruption. These reservoirs are the primary barrier to achieving a functional cure for HIV, defined as sustained viral suppression without the need for ongoing therapy. The persistence of latent reservoirs is a complex biological phenomenon. HIV integrates its proviral DNA into the host genome, particularly in long-lived memory CD4+ T cells, where it remains transcriptionally silent and invisible to both the immune system and ART [5, 6]. Despite decades of research, strategies to target and eradicate these reservoirs, such as latency-reversing agents and immune-based therapies, have shown limited success. This has spurred interest in novel approaches, including gene editing technologies, to directly target and excise integrated HIV DNA. CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) has emerged as a groundbreaking tool for precise genome editing [7, 8]. By leveraging a guide RNA to target specific DNA sequences, CRISPR/Cas9 can introduce double-strand breaks, enabling the excision or disruption of integrated HIV proviral DNA. Preclinical studies have demonstrated the potential of CRISPR/Cas9 to eliminate latent reservoirs in cell lines, primary cells, and animal models. Early-phase clinical trials are now exploring the safety and efficacy of this approach in humans. This review examines the efficacy of CRISPR/Cas9 gene editing in eradicating HIV latent reservoirs in individuals on long-term ART. By synthesizing preclinical and clinical evidence, we aim to evaluate the potential of this technology to achieve a functional HIV cure, discuss its limitations, and identify key areas for future research.

THE BIOLOGY OF HIV LATENT RESERVOIRS

i. **Formation and Persistence of Latent Reservoirs:** Latent reservoirs are established early during HIV infection when the virus integrates its DNA into the host genome, particularly in CD4+ T cells [9, 10]. These cells can remain dormant for years, evading immune detection and ART. The stability of these reservoirs is a major obstacle to curing HIV.

ii. **Challenges in Targeting Latent Reservoirs:** Latent reservoirs are heterogeneous, with proviral DNA integrated at various sites in the genome. Additionally, only a small fraction of integrated proviruses are replication-competent, complicating efforts to identify and target them. Current strategies, such as "shock and kill," have shown limited efficacy due to incomplete latency reversal and immune exhaustion.

CRISPR/CAS9: MECHANISMS AND APPLICATIONS

i. **Mechanisms of CRISPR/Cas9:** CRISPR/Cas9 is a RNA-guided gene-editing tool that introduces double-strand breaks at specific genomic locations[7, 8]. The cell repairs these breaks through non-homologous end joining (NHEJ) or homology-directed repair (HDR), enabling precise modifications such as gene knockout, excision, or correction.

ii. **Applications in HIV Research:** CRISPR/Cas9 has been used to target and excise integrated HIV proviral DNA, disrupt host genes essential for viral replication (e.g., CCR5), and engineer immune cells to resist HIV infection. These applications hold promises for eradicating latent reservoirs and achieving a functional cure.

PRECLINICAL EVIDENCE FOR CRISPR/CAS9 IN ERADICATING LATENT RESERVOIRS

i. **In Vitro Studies:** In Vitro studies using cell lines and primary CD4+ T cells have demonstrated the ability of CRISPR/Cas9 to exercise HIV proviral DNA and reduce viral replication [11, 12]. For example, a 2016 study showed that CRISPR/Cas9 could remove HIV DNA from latently infected T cells, leading to reduced viral reactivation.

ii. **Animal Models:** Humanized mouse models have provided further evidence of CRISPR/Cas9's efficacy. Studies have shown that CRISPR/Cas9 can reduce viral loads and reservoir sizes in HIV-infected mice, with some achieving sustained viral suppression. However, challenges such as incomplete excision and off-target effects remain.

CLINICAL EVIDENCE AND EARLY-PHASE TRIALS

i. **Phase I/II Trials:** Early-phase clinical trials are evaluating the safety and efficacy of CRISPR/Cas9 in HIV-positive individuals on long-term ART [13]. For example, a recent trial tested the use of CRISPR/Cas9 to excise proviral DNA in ART-suppressed individuals. Preliminary results indicate that the intervention is well-tolerated, with no serious adverse events reported.

ii. **Challenges in Clinical Translation:** Clinical translation of CRISPR/Cas9 faces several challenges, including delivery efficiency, immune responses, and the persistence of residual reservoirs. Additionally, long-term safety data are lacking, necessitating further research.

CHALLENGES AND LIMITATIONS

i. **Off-Target Effects:** CRISPR/Cas9 can induce unintended mutations at off-target sites, raising concerns about genomic instability and oncogenic potential [11]. Advances in high-fidelity Cas variants and improved delivery systems are addressing this issue, but it remains a significant barrier.

ii. **Delivery Efficiency:** Efficient delivery of CRISPR/Cas9 components to target cells, particularly latent reservoirs in hard-to-reach anatomical sites, is a major challenge[14, 15]. Viral vectors, lipid nanoparticles, and ex vivo editing strategies are being explored to improve delivery.

iii. **Immune Responses:** The immune system may recognize CRISPR/Cas9 components as foreign, leading to immune activation or rejection of edited cells. Strategies to mitigate immune responses, such as using immune-evasive Cas proteins, are under investigation.

iv. **Persistence of Residual Reservoirs:** Despite CRISPR/Cas9 intervention, residual latent reservoirs may persist, necessitating combination approaches with latency-reversing agents or immune-based therapies.

FUTURE DIRECTIONS

i. **Enhancing Precision and Efficiency:** Developing high-fidelity Cas variants and optimizing delivery systems will be critical for improving the precision and efficiency of CRISPR/Cas9-based interventions [16].

ii. **Combination Therapies:** Combining CRISPR/Cas9 with other cure strategies, such as latency-reversing agents, broadly neutralizing antibodies, or therapeutic vaccines, may enhance efficacy.

iii. **Long-Term Safety Studies:** Longitudinal studies are needed to assess the long-term safety and durability of CRISPR/Cas9-based interventions in humans.

iv. **Ethical and Regulatory Considerations:** The ethical implications of germline editing and the regulatory landscape for CRISPR/Cas9-based therapies must be carefully navigated [17].

CONCLUSION

CRISPR/Cas9 gene editing represents a transformative approach in the quest to eradicate HIV latent reservoirs and achieve a functional cure. Preclinical and early clinical studies have demonstrated the feasibility of exercising integrated proviral DNA and reducing viral loads, offering hope for a future where HIV can be effectively cured. However, significant challenges remain, including off-target effects, delivery efficiency, immune responses, and the persistence of residual reservoirs. Addressing these challenges through technological advancements, combination therapies, and rigorous clinical testing will be essential for realizing the potential of CRISPR/Cas9 in HIV cure research. The progress made thus far underscores the promise of CRISPR/Cas9 technology, but it also highlights the complexity of translating these innovations into safe and effective therapies. As research continues to advance, interdisciplinary collaboration among scientists, clinicians, ethicists, and policymakers will be crucial to navigating the scientific, ethical, and regulatory landscapes. While the road ahead is complex, the potential to achieve a functional HIV cure through CRISPR/Cas9 gene editing offers hope for millions of individuals living with HIV worldwide, marking a significant step forward in the fight against this global health challenge.

REFERENCES

1. Alum, E.U., Uti, D.E., Ugwu, O.P.C., Alum, B.N.: Toward a cure - Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review. Medicine (United States). 103, e38768 (2024). https://doi.org/10.1097/MD.0000000000038768
2. Ugo Alum, E., Okechukwu, U.P., Ifeanyi Obeagu, E., Maduabuchi Aja, P.: Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. (2023). https://doi.org/10.58538/IJIAR/2048
3. Obeagu, E.I., Obeagu, G.U., Alum, E.U., Ugwu, O.P.-C.: Comprehensive Review of Antiretroviral Therapy Effects on Red Blood Cells in HIV Patients. INOSR Experimental Sciences. 12, 63–72 (2023). https://doi.org/10.59298/INOSRES/2023/6.3.21322
4. Alum, E.U., Obeagu, E.I., Ugwu, O.P.C., Samson, A.O., Adepoju, A.O., Amusa, M.O.: Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 102, e35673 (2023). https://doi.org/10.1097/MD.0000000000035673
5. Balasubramaniam, M., Pandhare, J., Dash, C.: Immune Control of HIV. J Life Sci (Westlake Village). 1, 4 (2019). https://doi.org/10.36069/jols/20190603
6. Painter, M.: Mechanisms of Human Immunodeficiency Virus (HIV) Persistence and Strategies to Elicit Cytotoxic T Lymphocyte-Mediated Clearance of HIV-Infected Cells. (2020). https://doi.org/10.7302/31
7. Irfan, M., Majeed, H., Iftikhar, T., Ravi, P.K.: A review on molecular scissoring with CRISPR/Cas9 genome editing technology. Toxicol Res (Camb). 13, (2024). https://doi.org/10.1093/TOXRES/TFAE105
8. Ferreira, P., Choupina, A.B.: CRISPR/Cas9 a simple, inexpensive and effective technique for gene editing. Mol Biol Rep. 49, 7079–7086 (2022). https://doi.org/10.1007/S11033-022-07442-W/FIGURES/3
9. Sengupta, S., Siliciano, R.F.: Targeting the Latent Reservoir for HIV-1. Immunity. 48, 872–895 (2018). https://doi.org/10.1016/J.IMMUNI.2018.04.030/ASSET/5F2F3716-2018-4BC6-82D9-3ECE307B84F6/MAIN.ASSETS/GR2.JPG
10. Castro-Gonzalez, S., Colomer-Lluch, M., Serra-Moreno, R.: Barriers for HIV Cure: The Latent Reservoir. https://home.liebertpub.com/aid. 34, 739–759 (2018). https://doi.org/10.1089/AID.2018.0118
11. Lebbink, R.J., De Jong, D.C.M., Wolters, F., Kruse, E.M., Van Ham, P.M., Wiertz, E.J.H.J., Nijhuis, M.: A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Scientific Reports 2017 7:1. 7, 1–10 (2017). https://doi.org/10.1038/srep41968
12. Hultquist, J.F., Hiatt, J., Schumann, K., McGregor, M.J., Roth, T.L., Haas, P., Doudna, J.A., Marson, A., Krogan, N.J.: CRISPR–Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV–host factor interactions. Nature Protocols 2018 14:1. 14, 1–27 (2018). https://doi.org/10.1038/s41596-018-0069-7
13. Xiao, Q., Guo, D., Chen, S.: Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy. Front Cell Infect Microbiol. 9, 446528 (2019). https://doi.org/10.3389/FCIMB.2019.00069/PDF
14. Macchione, M.A., Bedoya, D.A., Figueroa, F.N., Muñoz-Fernández, M.Á., Strumia, M.C.: Nanosystems Applied to HIV Infection: Prevention and Treatments. International Journal of Molecular Sciences 2020, Vol. 21, Page 8647. 21, 8647 (2020). https://doi.org/10.3390/IJMS21228647
15. Mastrangelo, A., Gama, L., Cinque, P.: Strategies to target the central nervous system HIV reservoir. Curr Opin HIV AIDS. 19, 133–140 (2024). https://doi.org/10.1097/COH.0000000000000847

16. Khoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A.A., Hosseinkhani, S.: Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine. Genes Dis. 11, 268–282 (2024). https://doi.org/10.1016/J.GENDIS.2023.02.027
17. Baumann, M.: CRISPR/Cas9 genome editing – new and old ethical issues arising from a revolutionary technology. Nanoethics. 10, 139–159 (2016). https://doi.org/10.1007/S11569-016-0259-0/METRICS

CITE AS: Wambui Kibibi J. (2025). Efficacy of CRISPR/Cas9 Gene Editing in Eradicating HIV Latent Reservoirs in Individuals on Long-term ART. EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH, 7(3):110-113